Literature DB >> 2106766

The economics of hypertension and stroke.

G T Smith1.   

Abstract

The prevention of stroke through the control of hypertension is cost-effective economically and medically. A reduced incidence of stroke generates savings to the health service in hospital and surgical costs, and the avoidance of premature mortality means survivors contribute more to the economy as a result of extra working years. In addition to financial benefits, antihypertensive agents can also improve a patient's quality of life. This can be measured with a variety of health profiles or indexes and is often expressed together with life expectancy in quality-adjusted life years. This article examines the benefits produced by the effective control of hypertension, taking data from England and Wales during the past 30 years.

Entities:  

Mesh:

Year:  1990        PMID: 2106766     DOI: 10.1016/s0002-8703(05)80052-3

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal.

Authors:  Christopher Evans; Manouche Tavakoli; Bruce Crawford
Journal:  Health Care Manag Sci       Date:  2004-02

2.  Novel monoclonal antiendotoxin antibody therapy: efficacy at any price?

Authors:  W K Fant
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

Review 3.  The economics of shared care packages.

Authors:  S M McGhee; A J Hedley
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

Review 4.  The problem of quality of life.

Authors:  S M Hunt
Journal:  Qual Life Res       Date:  1997-04       Impact factor: 4.147

Review 5.  Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.

Authors:  F Wisløff; N Gulbrandsen; E Nord
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

6.  Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.

Authors:  E Nord; F Wisløff; M Hjorth; J Westin
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

7.  Some guidelines on the use of cost effectiveness league tables.

Authors:  J Mason; M Drummond; G Torrance
Journal:  BMJ       Date:  1993-02-27

Review 8.  Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.

Authors:  K S Woo; H D White
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.